pursuing transparency in the life science industry: threat ......report the european transparency...
TRANSCRIPT
Pursuing Transparency in the Life Science
industry: Threat or Business Advantage?
Sabrina Suetens, General Manager
Emeline Blin, Product Manager Compliance
1. The Transparency Agenda
2. Legal, Transversal and Operational Challenges
3. From Pharma 2.0 to Patient Centricity
4. What’s in it for me?
Agenda
The
Transparency
Agenda: A
European &
Belgian
Insight
Report
The European Transparency Agenda
2015 2014 2013
Individual
disclosure begins
EFPIA Transparency
Guidelines
EFPIA Code of
Practice
Data collection by
member companies
Contribution to costs
related to Events
Fees for Service and
Consultancy
Donations
and Grants
Research &
Development
Individual disclosure Aggregate disclosure
Central Platform
HCP (AR78)/ HCO
The Belgian Transparency Agenda
Transfers of Value 2016, Once a year
Visa applications
Transparency
is Legal,
Transversal
and
Operational
challenge
Think Global, Act Local
Self-Regulatory
Legal Provision
EFPIA HCP/HCO DISCLOSURE CODE
Laws vs code of
conduct
Definitions
Data Privacy
Thresholds Industry
involved
Think Global, Act Local
Engagement of HCP
Speaker program / Consulting
Clinical Trials/ Medical Publications
Sponsorships / Donation & Grants
Market Research/ Clinical Trials
Pr J E Smith
UK Hospital
Dr John
Smith Dr Smith Mr J. Smith
Sales &
Marketing
R&D and Medical
Affairs
Corporate
Affairs
Third Party
Vendor/Partners
Unique Identification
Geographies Product Business Unit Customer Vendors
Process Alignment across the Enterprise
From
Pharma 2.0
to Patient
Centricity
Pharma 3.0
Pharma 1.0 Pharma 2.0 Pharma 3.0
Physician Payor
Patient
R&D Productivity
Patent Cliff
Globalization
Demographics
Pricing & Reimbursement
Healthcare Reform
Health IT
Consumerism
Value mining
Business
Model
Customer
Drivers of
change
Patient Centricity
Intent and
Culture
Access and
Pricing
Respecting
patient value
Quality
information
Patient Safety Communications
Transparency
Engagement and
involvement
What’s
in it
for me?
Brand
Awareness
Focus
Commercial
Model on
Product
Marketability
Company
Reputation
+
+
Transform Compliance from Cost to
Competitive Advantage
Patient
centricity
Integrity
Transparency High-quality,
useful products
High-quality
information for
patients
On 800 patient groups from
43 countries and differing
specialties
35.4% (…) stated that multinational
pharma companies had either
an “excellent” or “good”
reputation in 2013, placing
pharma 7th in the
league table of healthcare
industries.*
The Corporate reputation of Pharma
The Patient Perspective
Corporate
Reputation
KPI’s
*Patient View – The Corporate Reputation of Pharma- the Patient Perspective – February 2014
HCP Payment Scrutiny
Advancement of Medical Science
HCP Scientific Contributions
Valuable Industry Relationships
Innovation and Product Development
Public Perception
Media Scrutiny
Aggregate Spend Disclosure Laws
« Meet the high standards of integrity that patients,
governments and other stakeholders expect » EFPIA, June 2013
The increasing professionalization of
hospitals generates pressure in the
entire supply chain
Identify and analyze customers on which you invest the most.
Analyze spending patterns and identify corresponding customers.
How are your marketing investment allocated?
When do you invest and on which items?
A 360° view of customer’s spend over time.
Leverage your Aggregated Spend solution
into a Business Intelligence Tool
Get an analytics
views of your
promotional
spend.
Reputation knows no national
borders
Conclusion
Turn the transparency
requirements into an essential,
value-generating business
advantage.
Thank You! Sabrina Suetens, General Manager, Cegedim
Emeline Blin, Product Manager Compliance, Cegedim
Sample Management AggregateSpend 360 OneKey